Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: C-reactive protein, Polymyalgia rheumatica, Red blood cell sedimentation rate
Clinical narrative: Polymyalgia Rheumatica; recurrence of the classic polymyalgia rheumatica symptoms; This literature-non-study case was reported in a literature article and describes the occurrence of POLYMYALGIA RHEUMATICA (Polymyalgia Rheumatica) and POLYMYALGIA RHEUMATICA (recurrence of the classic polymyalgia rheumatica symptoms) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.   LITERATURE REFERENCE:     No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced POLYMYALGIA RHEUMATICA (Polymyalgia Rheumatica) (seriousness criterion medically significant) and POLYMYALGIA RHEUMATICA (recurrence of the classic polymyalgia rheumatica symptoms) (seriousness criterion medically significant). The patient was treated with PREDNISONE at a dose of 15 milligram. At the time of the report, POLYMYALGIA RHEUMATICA (Polymyalgia Rheumatica) and POLYMYALGIA RHEUMATICA (recurrence of the classic polymyalgia rheumatica symptoms) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, C-reactive protein: elevated. On an unknown date, Red blood cell sedimentation rate: elevated and elevated  after booster dose.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  Patient developed arm and thigh stiffness a week before the second dose while receiving primary Moderna vaccine series. Patient had an elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), so patient was started on low-dose steroids, which were weaned down over a five-month period. Three weeks after receiving Moderna booster, patient had a recurrence of the classic polymyalgia rheumatica symptoms and elevated ESR. Patient responded to prednisone 15 mg with a successful taper over eight month.  Authors concluded that the goal of this article was to prompt physicians about the possibility of PMR incidence after patients received vaccinations for severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). PMR could be debilitating to the quality of life of patients. Knowing this association allowed for more timely and competent treatment. PMR following SARS-CoV-2 vaccinations was continuously being observed in the medical field. Increased knowledge might help prevent the recurrence with subsequent doses.  Company Comment: This is a literature non-study case concerning a 69-year-old, female patient with no reported medical history, who experienced the serious (due to medically significant) unexpected, event of Polymyalgia rheumatica (recurrence of polymyalgia rheumatica symptoms). The event occurred approximately 3 weeks after receiving her booster mRNA-1273 vaccine. She had developed arm and thigh stiffness a week before the second dose while receiving her primary Moderna vaccine series. She had an elevated C reactive protein and erythrocyte sedimentation rate so she was started on low-dose steroids, which were weaned down over a five-month period. Three weeks after receiving her Moderna booster, she had a recurrence of the classic polymyalgia rheumatica symptoms and elevated ESR. She responded to prednisone 15 mg with a successful taper over eight months. The outcome of the event was reported as recovered. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Sender's Comments: This is a literature non-study case concerning a 69-year-old, female patient with no reported medical history, who experienced the serious (due to medically significant) unexpected, event of Polymyalgia rheumatica (recurrence of polymyalgia rheumatica symptoms). The event occurred approximately 3 weeks after receiving her booster mRNA-1273 vaccine. She had developed arm and thigh stiffness a week before the second dose while receiving her primary Moderna vaccine series. She had an elevated C reactive protein and erythrocyte sedimentation rate so she was started on low-dose steroids, which were weaned down over a five-month period. Three weeks after receiving her Moderna booster, she had a recurrence of the classic polymyalgia rheumatica symptoms and elevated ESR. She responded to prednisone 15 mg with a successful taper over eight months. The outcome of the event was reported as recovered. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.